Alembic site hit with warning letter on patient consent concerns
Alembic's bioequivalence site received an FDA warning letter over informed consent concerns.
Alembic Pharmaceuticals
NSE: APELLTD ~$3B MCAP
Alembic Pharmaceuticals is an Indian multinational pharmaceutical company focused on the development, manufacturing, and commercialization of generic pharmaceutical products. Recently received an FDA warning letter on its bioequivalence site over informed consent concerns.
Company Info
Sector:Pharmaceuticals
Headquarters:Vadodara, Gujarat, India
Founded:1907
Website:alembicpharmaceuticals.com/
Upcoming Milestones & Key Dates
Q3-Q4 2026
Regulatory
FDA warning letter remediation
Clinical Development Pipeline
Generic portfolio
Target: MultipleANDA pipeline
Target: MultipleRecent News
Leadership Team
Pranav Amin
Managing Director
Shaunak Amin
Whole-time Director
To be confirmed
Chief Scientific Officer